| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Fractional fall in hemoglobin at day 3 | |||
| mean % fall | 12.6 | 13.2 | .682 |
| 95% CI | 10.9–14.3 | 10.9–15.4 | |
| Hemoglobin nadir (g/dL) | |||
| median | 10.5 | 10.3 | .840 |
| IQR (range) | 9.3–11.3 (6.7–14.1) | 9–11.8 (6.4–13.2) | |
| Time to hemoglobin nadir (days) | |||
| median | 2 | 2 | .942 |
| IQR (range) | 2–3 (0–42) | 1–4 (0–28) | |
| Prevalence of anemia at day 28 | |||
| % | 24.4 | 54.8 | .004 |
| 95% CI | 12.9–39.5 | 38.7–70.2 | |
| n/N | 11/45 | 23/42 | |
| AORa (95% CI) | 6.8 (2.1–22.0) | .001 | |
| Prevalence of anemia at day 42b | |||
| % | 25.7 | 53.3 | .023 |
| 95% CI | 12.5–43.3 | 34.3–71.7 | |
| n/N | 9/35 | 16/30 | |
| AORa (95% CI) | 3.7 (1.0–13.5) | .045 | |
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Fractional fall in hemoglobin at day 3 | |||
| mean % fall | 12.6 | 13.2 | .682 |
| 95% CI | 10.9–14.3 | 10.9–15.4 | |
| Hemoglobin nadir (g/dL) | |||
| median | 10.5 | 10.3 | .840 |
| IQR (range) | 9.3–11.3 (6.7–14.1) | 9–11.8 (6.4–13.2) | |
| Time to hemoglobin nadir (days) | |||
| median | 2 | 2 | .942 |
| IQR (range) | 2–3 (0–42) | 1–4 (0–28) | |
| Prevalence of anemia at day 28 | |||
| % | 24.4 | 54.8 | .004 |
| 95% CI | 12.9–39.5 | 38.7–70.2 | |
| n/N | 11/45 | 23/42 | |
| AORa (95% CI) | 6.8 (2.1–22.0) | .001 | |
| Prevalence of anemia at day 42b | |||
| % | 25.7 | 53.3 | .023 |
| 95% CI | 12.5–43.3 | 34.3–71.7 | |
| n/N | 9/35 | 16/30 | |
| AORa (95% CI) | 3.7 (1.0–13.5) | .045 | |
Bold was used to highlight statistically significant values (P < .05).
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; IQR, interquartile range.
a After controlling for the following confounding factors: baseline parasite count, hemoglobin, age, sex.
b Post primaquine administration.
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Fractional fall in hemoglobin at day 3 | |||
| mean % fall | 12.6 | 13.2 | .682 |
| 95% CI | 10.9–14.3 | 10.9–15.4 | |
| Hemoglobin nadir (g/dL) | |||
| median | 10.5 | 10.3 | .840 |
| IQR (range) | 9.3–11.3 (6.7–14.1) | 9–11.8 (6.4–13.2) | |
| Time to hemoglobin nadir (days) | |||
| median | 2 | 2 | .942 |
| IQR (range) | 2–3 (0–42) | 1–4 (0–28) | |
| Prevalence of anemia at day 28 | |||
| % | 24.4 | 54.8 | .004 |
| 95% CI | 12.9–39.5 | 38.7–70.2 | |
| n/N | 11/45 | 23/42 | |
| AORa (95% CI) | 6.8 (2.1–22.0) | .001 | |
| Prevalence of anemia at day 42b | |||
| % | 25.7 | 53.3 | .023 |
| 95% CI | 12.5–43.3 | 34.3–71.7 | |
| n/N | 9/35 | 16/30 | |
| AORa (95% CI) | 3.7 (1.0–13.5) | .045 | |
| Variable . | Artesunate-Mefloquine n = 54 . | Chloroquine n = 49 . | P Value . |
|---|---|---|---|
| Fractional fall in hemoglobin at day 3 | |||
| mean % fall | 12.6 | 13.2 | .682 |
| 95% CI | 10.9–14.3 | 10.9–15.4 | |
| Hemoglobin nadir (g/dL) | |||
| median | 10.5 | 10.3 | .840 |
| IQR (range) | 9.3–11.3 (6.7–14.1) | 9–11.8 (6.4–13.2) | |
| Time to hemoglobin nadir (days) | |||
| median | 2 | 2 | .942 |
| IQR (range) | 2–3 (0–42) | 1–4 (0–28) | |
| Prevalence of anemia at day 28 | |||
| % | 24.4 | 54.8 | .004 |
| 95% CI | 12.9–39.5 | 38.7–70.2 | |
| n/N | 11/45 | 23/42 | |
| AORa (95% CI) | 6.8 (2.1–22.0) | .001 | |
| Prevalence of anemia at day 42b | |||
| % | 25.7 | 53.3 | .023 |
| 95% CI | 12.5–43.3 | 34.3–71.7 | |
| n/N | 9/35 | 16/30 | |
| AORa (95% CI) | 3.7 (1.0–13.5) | .045 | |
Bold was used to highlight statistically significant values (P < .05).
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; IQR, interquartile range.
a After controlling for the following confounding factors: baseline parasite count, hemoglobin, age, sex.
b Post primaquine administration.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
